Clinical Design and Objectives

Regeneron is evaluating the efficacy and safety of ubamatamab and REGN7075 in a Phase 2 clinical trial that began on March 18, 2026. The trial aims to assess the effects of the combination therapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to determine the anti-cancer activity and adverse events associated with the two antibodies. The study will also measure serum concentrations and antibody production. Furthermore, the trial will investigate the use of sarilumab in combination to manage potential immune-related adverse events associated with ubamatamab.

Target Patient Population and Expected Outcomes

The trial participants are adult patients with advanced or metastatic NSCLC who have shown resistance to prior treatments. The combination therapy, which combines a novel antigen target with an immune activation mechanism, is expected to have a synergistic effect on tumor suppression.

Differentiation from Existing Treatments

The current standard of care for first-line treatment involves a combination of PD-1/PD-L1 inhibitors and chemotherapy; however, resistance is a common issue. Ubamatamab targets a novel tumor antigen, and REGN7075 activates immune cells, providing a differentiated mechanism of action. The combination with sarilumab also focuses on managing antibody-related immune adverse events.

Potential Impact of Success

If the trial is successful, Regeneron will be able to add an innovative antibody combination to its portfolio of NSCLC treatments, providing a new growth driver for investors and partners. Conversely, failure would necessitate a re-evaluation of the combination antibody strategy.